Please use this identifier to cite or link to this item: https://bura.brunel.ac.uk/handle/2438/34188
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMohamed-Ahmed, R-
dc.contributor.authorRantell, A-
dc.contributor.authorRobinson, D-
dc.date.accessioned2026-11-17T10:47:37Z-
dc.date.available2026-11-17T10:47:37Z-
dc.date.issued2026-07-21-
dc.identifier.citationMohamed-Ahmed, R., Rantell, A. and Robinson, D. (2026) 'Comparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis', European Journal of Obstetrics & Gynecology and Reproductive Biology, 325, 115321, pp. 1–8. doi: 10.1016/j.ejogrb.2026.115321.en_GB
dc.identifier.issn0301-2115-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/34188-
dc.descriptionData availability: Data are available on request.en_GB
dc.description.abstractIntroduction: Overactive bladder (OAB) is defined as ‘urinary urgency with or without urinary urgency incontinence (UUI), usually associated with urinary frequency and/or nocturia, in the absence of urinary tract infection’. OAB is known to be a common disorder with a significant impact on quality of life.First line treatments include weight loss in those with a BMI > 30, bladder retraining and fluid advice. Pharmacotherapy treatment includes antimuscarinics and mirabegron, a beta 3 agonist.The National Institute of Clinical Excellence (NICE), has recently incorporated the use of a newer beta 3 agonist, vibegron, into its recommendations for the management of overactive bladder (OAB). There are no head-to-head studies which directly compare the efficacy of vibegron with mirabegron, an older beta 3 agonist. Aim: This network meta-analysis aims to compare the safety and efficacy of vibegron when compared to mirabegron and tolterodine, more longstanding treatments for OAB. Method: A systematic review was conducted to identify phase III randomised controlled trials, for patients with idiopathic OAB, which compared mirabegron and/or vibegron and/or tolterodine. The primary outcome was the change from baseline in episodes of urinary urgency (UU). The secondary outcomes assessed were:•Change from baseline in UUI.•Change from baseline in urinary frequency over 24 h.•Change from baseline in maximum voided volume per void (mL).•Adverse effects, including hypertension, dry mouth and constipation.The study was registered on PROSPERO (CRD 420250636077) and analysis was performed using MetaInsight. Results: Of the 2,647 identified articles, five studies were deemed suitable to include in the network meta-analysis.Results for the primary outcome included 5,317 patients and demonstrated a greater improvement in UU episodes in the vibegron group, when compared to placebo, tolterodine and mirabegron.Vibegron also ranked favourably in reduction in episodes of UUI and improvement in maximum voided volume per void. Whereas mirabegron had the greater improvement in reduction in episodes of urinary frequency. Adverse events: The incidence of any adverse event was highest in the vibegron group. Tolterodine had the highest rate of hypertension and dry mouth. Constipation was highest in the vibegron group. However, it is important to note the large heterogeneity in definitions of adverse events as well as discrepancy in their reporting. Conclusions: Vibegron appears to rank more favourably for improvement in episodes of UU, UUI and maximum voided volume per void, when compared to mirabegron and tolterodine. Mirabegron ranks more favourably for improvement in episodes of urinary frequency over 24 h.Mirabegron is least likely to be associated with hypertension, although reporting of adverse events is non-standardised and therefore may not be comparable.This network meta-analysis does not account for other factors which may influence drug therapy choice i.e. contraindications, difficulties with swallowing and available treatment options.en_GB
dc.description.sponsorshipThis research did not require any funding.en_GB
dc.format.extentpp. 1–8-
dc.format.mediumPrint-Electronic-
dc.languageEnglishen_GB
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.rightsRe-use licence for this version: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International-
dc.rightsLicence for published version: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectmirabegronen_GB
dc.subjectnetwork meta-anaylsisen_GB
dc.subjectoveractive bladderen_GB
dc.subjectsystematic reviewen_GB
dc.subjecttolterodineen_GB
dc.subjectVibegronen_GB
dc.subject.meshHumans-
dc.subject.meshAcetanilides-
dc.subject.meshPyrimidinones-
dc.subject.meshPyrrolidines-
dc.subject.meshThiazoles-
dc.subject.meshMuscarinic Antagonists-
dc.subject.meshTreatment Outcome-
dc.subject.meshUrinary Bladder, Overactive-
dc.subject.meshAdrenergic beta-3 Receptor Agonists-
dc.subject.meshUrological Agents-
dc.subject.meshTolterodine Tartrate-
dc.subject.meshHumans-
dc.subject.meshUrinary Bladder, Overactive-
dc.subject.meshThiazoles-
dc.subject.meshAcetanilides-
dc.subject.meshTolterodine Tartrate-
dc.subject.meshPyrrolidines-
dc.subject.meshUrological Agents-
dc.subject.meshAdrenergic beta-3 Receptor Agonists-
dc.subject.meshMuscarinic Antagonists-
dc.subject.meshTreatment Outcome-
dc.subject.meshPyrimidinones-
dc.subject.other1114 Paediatrics and Reproductive Medicine-
dc.subject.otherObstetrics & Reproductive Medicine-
dc.titleComparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysisen_GB
dc.typeArticleen_GB
dc.date.dateAccepted2026-07-14-
dc.identifier.doihttps://doi.org/10.1016/j.ejogrb.2026.115321-
dc.relation.isPartOfEuropean Journal of Obstetrics & Gynecology and Reproductive Biologyen_GB
pubs.publication-statusPublished-
pubs.volume325-
dc.identifier.eissn1872-7654-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/legalcode.en-
dcterms.dateAccepted2026-07-14-
dcterms.issued2026-07-21-
dc.date.updated2026-11-17T10:44:10Z-
dc.rights.holderThe Author(s)-
dc.contributor.orcidMohamed-Ahmed, R [0000-0002-6739-5014]-
dc.contributor.orcidRantell, Angie [0000-0002-9123-5352]-
dc.contributor.orcidRobinson, D [0000-0002-4879-6672]-
dc.identifier.number115321-
Appears in Collections:Department of Health Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2026 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license ( https://creativecommons.org/licenses/by/4.0/ ).2.6 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons